Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
Glioblastoma multiforme (GBM) is the most common and malignant brain tumor, and almost half of the patients carrying EGFR-driven tumor with PTEN deficiency are resistant to EGFR-targeted therapy. EGFR amplification and/or mutation is reported in various epithelial tumors. This series of studies aime...
Saved in:
Main Authors: | Kunyan He (Author), Guang-Xing Wang (Author), Li-Nan Zhao (Author), Xiao-Fang Cui (Author), Xian-Bin Su (Author), Yi Shi (Author), Tian-Pei Xie (Author), Shang-Wei Hou (Author), Ze-Guang Han (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020) -
Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Xiaohe Li, et al.
Published: (2019) -
EGFR Amplification and Glioblastoma Stem-Like Cells
by: Katrin Liffers, et al.
Published: (2015) -
Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification
by: Dekanić Andrea, et al.
Published: (2011) -
Spatial Lipidomics Reveals Anticancer Mechanisms of Bufalin in Combination with Cinobufagin in Tumor-Bearing Mice
by: Jinghui Zhang, et al.
Published: (2021)